간행물

생화학분자생물학회입니다.


EMM

4-1BB immunotherapy: advances and hurdles

  • 작성자

    Beom K. Choi
  • 작성일자

    2024-03-22
  • 조회수

    1046
Beom K. Choi( magetin@gmail.com )
2023-presentCEO, SamdaBiolab, South Korea
2023-presentCTO, InnobationBio, South Korea
2019-2023Principal Investigator, Biomedicine Production Branch, NCC, South Korea
2018-2022QA manager, Biomedicine Production Branch, NCC, South Korea
2011-2019Senior Scientist, Cancer Immunology Branch, NCC, South Korea
2008-2011Associate Scientist, Immune & Cell Therapy Branch, NCC, South Korea
2000-2004PhD, Department of Immunology and Biomedicine, University of Ulsan, South Korea
1997-1999MS, Department of Microbiology, Hannam University, South Korea

4-1BB immunotherapy: advances and hurdles

Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated immune functions. Numerous studies have demonstrated the involvement of 4-1BB in infection and tumor immunity. However, the clinical development of 4-1BB agonist antibodies has been impeded by the occurrence of strong adverse events, notably hepatotoxicity, even though these antibodies have exhibited tremendous promise in in vivo tumor models. Efforts are currently underway to develop a new generation of agonist antibodies and recombinant proteins with modified effector functions that can harness the potent T-cell modulation properties of 4-1BB while mitigating adverse effects. In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy.

Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4.
https://pubmed.ncbi.nlm.nih.gov/38172595/